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Abstract 
To facilitate the rapid purification of bacterial outer membrane vesicles (OMVs), we developed 
two plasmid constructs that utilize a truncated, transmembrane protein to present an exterior 
histidine repeat sequence. We chose OmpA, a highly abundant porin protein, as the protein 
scaffold and utilized the lac promoter to allow for inducible control of the epitope-presenting 
construct. OMVs containing mutant OmpA-His6 were purified directly from Escherichia 
coli culture media on an immobilized metal affinity chromatography (IMAC) Ni-NTA resin. This 
enabling technology can be combined with other molecular tools directed at OMV packaging to 
facilitate the separation of modified/cargo-loaded OMV from their wt counterparts. In addition to 
numerous applications in the pharmaceutical and environmental remediation industries, this 
technology can be utilized to enhance basic research capabilities in the area of elucidating 
endogenous OMV function. 
Keywords: Escherichia coli; Outer membrane vesicles (OMVs); Extracellular vesicles; Affinity 
purification; IMAC; His-tag 
1 Introduction 
There is a growing list of bacterial and mammalian cell types that release extracellular 
vesicles (EVs), outer membrane vesicles (OMVs) or exosomes that carry out various in vivo 
cellular functions that include: cell-cell communication, host defense mechanisms, gene transfer 
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and delivery of various virulence factors [1–6]. To date, all investigated Gram-positive and Gram-
negative bacteria have been shown to release EV/OMV from their outer surface [7–9]. While the 
OMVs of Gram-negative bacteria have been extensively studied for several decades, little is 
known about the EVs of Gram-positive bacteria. While the proteoliposomes isolated from both 
Gram-positive and Gram-negative bacteria are morphologically similar, ranging in size from 30 to 
200 nm, the composition of these particles is highly variable, similar to the bacteria from which 
they are derived. Proteoliposomes are being increasingly implicated in many disease processes and 
have therefore gained much interest in the medical field for both elucidating disease progression 
as well as utilizing EV/OMV directly as therapeutic and vaccine pharmaceuticals [10–14]. 
Bacteria produce EV/OMV throughout their growth cycle, making production of these vesicles 
relatively simple; however, more efficient and accessible purification protocols are necessary to 
allow the true potential of EV/OMV and exosomes to be realized [10]. 
Purification of bacterial outer membrane vesicles and mammalian exosomes is a difficult 
process that often requires expensive equipment and complex purification protocols. Most 
commonly, EVs/OMVs are purified via ultracentrifugation, density gradient fractionation, 
immunoaffinity, precipitation or ultrafiltration techniques [15]. Ultracentrifugation, which is 
utilized for both pelleting EV/OMV and density gradient fractionation, requires centrifugal forces 
of 100,000 × g or greater, necessitating access to expensive and specialized centrifugation 
equipment. Additionally, successful pelleting of EVs/OMVs requires several hours of continuous 
operation at these speeds, which is a substantial time investment. Ultrafiltration techniques are less 
expensive, but are not as widely used in the field due to difficulties that arise when separating 
EVs/OMVs purely based on size [16]. The EV/OMV hydrodynamic diameter size range can 
sometimes significantly overlap with protein and cell fragments that they are being separated from, 
often resulting in poor size-based separations [8]. Immunoaffinity purification protocols utilize 
various immobilized EV/OMV-specific antibodies, but are limited to the repertoire of available 
antibodies against externally facing endogenous epitopes, that also may vary between bacterial 
strains and relative abundance within an EV/OMV population. Here we demonstrate the proof of 
concept for utilizing common immobilized metal affinity chromatography (IMAC) protein 
purification protocols for the affinity purification of bacterial EVs/OMVs through incorporation 
of a non-native histidine amino acid repeat sequence (His-tag). 
IMAC affinity purification is arguably the most commonly utilized recombinant protein 
purification technique for both laboratory and industrial scale applications due to its exceptionally 
simple and relatively inexpensive implementation into downstream protein processing [17]. The 
technique requires the addition of a simple multiple histidine repeat, typically 3 to 6 residues in 
length, to a recombinant target protein. While, typically, the His-tag is appended to the N- or C-
termini of the target protein, it has been shown that internal sequences can also be utilized, albeit 
with decreased affinity. During purification, the His-tag coordinates to an immobilized divalent 
metal anchored to the resin via a trinitriloacetic acid group. Unlike other affinity capture resins, 
the IMAC system has tunable affinity based on the species of the sequestered metal ion. Typically, 
IMAC resins can be functionalized with Cu2+, Ni2+, Zn2+, Co2+, or Cd2+ ions, each possessing their 
own specific affinities and benefits [18,19]. 
Utilizing Escherichia coli as a model organism, we engineered two plasmid-encoded 
transmembrane proteins that present His-tag sequences to the outer surface of the cell membrane. 
We chose the porin protein OmpA as a scaffold for our construct, as the endogenous protein is 
highly abundant in bacterial outer membranes, and induction of the mutant OmpA constructs 
would not prove lethal to the bacterium [20–22]. Herein, we demonstrate that both a short 3-
histidine (His3) repeat within an exterior protein loop of OmpA and an extended 6-histidine (His6) 
repeat at the protein terminus can be used for the rapid purification of OMVs. While the bacterium 
chosen for these preliminary studies was a model E. coli strain, the technique described here could 
be broadly applied to other bacterial and mammalian species for the production and isolation of 
biologically derived proteoliposomes for various industrial and therapeutic applications following 
the addition of the His-tag to a membrane protein of the target organism. 
2 Materials and methods 
2.1 Materials 
Precast Mini-PROTEAN TGX 4–15% gradient gels were purchased from Bio-Rad 
(Hercules, CA, USA). A mouse anti-6xHis-tag antibody and alkaline phosphatase-conjugated anti-
mouse secondary antibody were purchased from Life Technologies (Frederick, MD). GelCode 
blue protein stain, 1-step NBT/BCIP precipitating substrate, DiI (1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate) lipophilic membrane stain and HisPur™ Ni-NTA resins 
were purchased from Thermo Scientific (Rockford, IL, USA). All other buffer salts and reagents, 
including imidazole, were purchased from Sigma-Aldrich (St. Louis, MO, USA). All 
measurements were carried out in triplicate and data represent means ± standard deviations. 
2.2 Construction of E. coli expression plasmids 
Genes encoding two OmpA variants containing a histidine epitope tag were synthesized 
by GenScript (Piscataway, NJ, USA) in a pUC57 shuttle vector with flanking NcoI and NotI 
restriction sites. The first construct consisted of native OmpA with the unessential C-terminal 
domain portion deleted and an internal His3 positioned in one of the external loops. Synthesized 
plasmids were digested with NcoI-HF and NotI-HF (New England Biolabs, Ipswich, MA, USA) 
and cloned into identical sites in the pET22b expression vector (Novagen, Billerica, MA, USA). 
Constructs were verified by sequencing. The Lpp′ OmpA (46-159) construct originally described 
by Stathopoulus et al. was modified with a glycine-serine linker sequence and short multiple 
cloning site at the 3′ end [23]. The gene cassette was synthesized by Genscript and cloned to a 
shuttle vector. The cassette was excised from the shuttle vector via XbaI – XhoI restriction 
digestion and cloned to the pET28 expression vector. This ligation strategy incorporated the C-
terminal His6-epitope. 
2.3 OMV-conditioned media preparation 
E. coli strain BL21 (DE3) containing the pET22 OmpA-His3 or pET 28 Lpp′-OmpA-His6 
plasmid was maintained on solid medium and expanded in overnight cultures in the presence of 
ampicillin (100 μg/mL) or kanamycin (25 μg/mL) to ensure plasmid maintenance. One mL of 
overnight culture was used to inoculate 100 mL of Terrific Broth in baffled culture flasks. The 
culture was allowed to grow for 3 h until an OD600 of 0.6–0.8 was reached. Isopropyl β-D-
thiogalactopyranoside was then added to a final concentration of 0.5 mM and the culture was 
allowed to grow for an additional 18 h at 37 °C. All conditioned bacterial culture media 
postexpansion was centrifuged two times at 7000 × g for 15 min at 4 °C to remove intact bacteria 
from the vesicle preparation. The resulting culture media was then filtered using a 0.45 μm 
biologically compatible filter to further remove large aggregates and undesired cellular material 
prior to IMAC purification. 
2.4 His-tag vesicle purification 
His-tag purification was carried out per the manufacturer's recommended protocol via a 
gravity-flow column or in solution batch incubation with the HisPur™ Ni-NTA resin. In brief, 
2 mL of prewashed resin were added directly to prepared culture media and allowed to incubate at 
4 °C for 1 h while mixing. The mixture was centrifuged at 700 × g to recover the resin decanting 
the OMV-depleted culture media. The resin was then transferred to a gravity column and washed 
with 2–3 column volumes of PBS containing 25 mM imidazole at pH 7.4 collecting equi-volume 
fractions for further analysis. Captured OMVs were then eluted from the resin with 1–2 column 
volumes of PBS elution buffer containing 250 mM imidazole, being sure to collect the free 
solubilized OMV in equi-volume fractions. 
2.5 SDS-PAGE and western blot analysis 
The samples were run on a gradient (4–15%) SDS-PAGE gel with a Tris-glycine running 
buffer under reducing conditions at 90 V for 90 min, and were transferred to a nitrocellulose 
membrane at 90 V for 90 min in a 10% MeOH transfer buffer. The membrane was probed with 
1:5000 dilution of mouse anti-6 × His-tag for 1 h and a 1:5000 dilution of an alkaline-phosphatase-
conjugated anti-mouse secondary antibody at room temperature (RT). A chromogenic alkaline 
phosphatase substrate was used to detect the His-tagged mutants. SDS-PAGE gels were GelCode-
Blue-stained for 30 min and destained for 4 h. All gel and blot images were taken on a Bio-Rad 
ChemiDoc imager. 
2.6 Confocal microscopy 
Vesicles were labeled with DiI (Life Technologies) following the manufacturer's protocol 
utilizing a 1:5000 dilution of a 1 mM stock solution. Samples were incubated for 20 min at 37 °C 
in PBS. All transmission and fluorescence images were taken on a Nikon Eclipse TE2000-E 
confocal microscope using EZ-C1 spectral imaging software. All fluorescence images were taken 
using a 20× objective using a 650LP red filter, medium (60 m) pinhole and 98 gain. Image analysis 
and z-stacking were performed on NIS Elements AR imaging software 3.10. All images were 
processed with identical parameters for direct comparison. 
2.7 SEM 
The morphologies of the vesicles were observed by scanning electron microscopy (Zeiss 
LEO 1550, Jena, Germany). The vesicles were snap-frozen in liquid nitrogen followed by 
lyophilization for 24 h. Samples were cast onto aluminum holders and sputter-coated with ca. 5 nm 
of gold (Cressington 108auto, Hertfordshire, UK). 
2.8 Nanosight 
Vesicle sizing and quantitation was performed on a NanoSight LM10 system (Salisbury, 
UK) using NTA 2.3 Nanoparticle Tracking and Analysis software. Samples were diluted 1000-
fold, and camera shutter (13.8 ms) and gain (324) were manually optimized to enhance data 
collection. Videos (90 s) were taken and frame sequences were analyzed under autoparticle 
detection and tracking parameters: detection threshold, pixel blur, min track length and min 
expected particle size. All samples were run at RT and allowed to equilibrate prior to analysis. 
3 Results and discussion 
3.1 Design of His-tag purification constructs 
In order to utilize an affinity tag purification technique such as IMAC, a non-native 
histidine repeat must be incorporated into an exterior facing permissive protein domain. This 
protein must be expressed in relatively high abundance and also must be present in the released 
OMV. To demonstrate different potential ways in which IMAC OMV purification can be 
implemented, two different constructs were developed incorporating a His-tag into an exterior 
facing protein domain (1) mutant OmpA-His3 and (2) mutant Lpp′-OmpA-His6 (construct 
sequences can be found in Supporting Information Fig. S1). OmpA is a highly expressed 
transmembrane porin protein implicated in the transfer of small molecules across the bacterial 
outer membrane which is also present in subsequent OMV [21]. In the case of the OmpA-His3 
mutant, a 3xHis-tag was incorporated in an exterior facing transmembrane loop to a truncated form 
of OmpA which lacked the periplasmic domain which binds to the peptidoglycan layer 
(Fig. 1A) [22,24,25]. This construct has been utilized by our laboratory previously in combination 
with a split protein system to direct the lumenal packaging of an active enzyme at either the N- or 
C-terminus of the recombinant truncated OmpA [26]. An internal modification that is directly 
linked to an external affinity tag has beneficial consequences for selectively purifying only cargo-
loaded OMV in the presence of native OMV and contaminating proteins. The second construct 
that was developed, Lpp′-OmpA-His6, simply adds an exterior facing 6xHis-tag (Fig. 1B) to the 
OMV surface. In this construct, a lipoylation sequence (Lpp′) directs a minimal OmpA scaffold 
(residues 46 - 159) which encode five transmembrane domains [27–29]. Described by 
Stathopoulus et al., this construct allows recombinant proteins, represented in this construct as a 
His-tag, to be presented to the exterior surface of the bacterial outer membrane [23]. Both 
constructs, which are under the control of an inducible promoter, result in high abundance of the 
recombinant protein and His-tag in the OMV. 
 Fig. 1 A) Schematic representation of the bacterial OMVs displaying the truncated OmpA 
embedded in the lipid bilayer displaying the location of the externally facing His-tag and 
internally modifiable N- and C-termini. B) Schematic representation of Lpp′-OmpA-His6 
construct. C) Representation of a complex OMV containing numerous surface modifications, 
transmembrane proteins and loaded cargo. 
 
For all subsequent experiments involving the characterization and purification of OMV, 
the bacteria producing both OmpA-His mutant variants were examined. In all instances, no 
significant differences were observed between the two constructs. Both exhibited similar size 
distribution, protein content and purification efficiencies. Therefore, unless otherwise noted within 
the text, results are shown for the Lpp′ OmpA His6 construct, but are representative of both mutant 
constructs. 
3.2 Vesicle production 
As both constructs were well tolerated by the bacterium under induction conditions, the 
bacterial growth and OMV production protocol were identical for both constructs. A 1 mL starter 
culture containing ampicillin or kanamycin to maintain selection was used to inoculate a 100 mL 
TB shaker flask placed at 37 °C. Once the resulting culture attained an OD600 of 0.6–0.8 
(approximately 3 h), IPTG was added to the culture at a final concentration of 0.5 mM to induce 
expression of the gene encoding the OmpA-His6 variant (Supporting Information Fig. S2). After 
an additional 18 h growth period, the cultures were centrifuged and passed through a 0.45 μm filter 
to remove intact bacteria and large cellular components prior to IMAC purification. For this proof 
of concept in which the His-tag is associated with a protein whose production is controlled via an 
inducible promoter, all of the initial OMV secreted by the bacteria prior to induction will not 
possess a His-tag and will therefore not be captured via IMAC. There are a number of 
modifications to the process that can minimize the number of OMV that do not display a His-tag, 
such as: swapping the growth media directly preceding plasmid induction to deplete non-His-tag 
containing OMV, adding the inducing agent at low levels at the start of culture expansion, or by 
utilizing homologous recombination techniques to ensure genomic expression of the OmpA-His6 
at all phases of growth. The variation that is optimal would need to be determined by the overall 
experimental goal, and any other limitations associated with each unique expression system. 
3.3 OMV purification via IMAC 
Once the intact bacteria and large bacterial fragments have been removed from the culture 
via centrifugation and membrane filtration, respectively, the resulting culture supernatant was 
subjected to IMAC purification. The culture supernatant was either applied via a gravity/pump to 
a prepacked IMAC resin column or, in an alternative protocol, IMAC resin was added directly to 
the culture supernatant in a slurry type purification protocol. Both techniques resulted in 
comparable capture and purification outcomes, and selection of one method over the other is 
largely experiment-specific. Processing of large volumes using the slurry method is often optimal, 
as flowing large volumes of culture supernatant over a packed resin bed can be time- and resource-
intensive. After incubating the resin with the culture supernatant in a slurry type purification for 
1 h, the slurry mixture was added to a gravity flow column to capture the resin. The resin bed was 
then washed with fresh buffer containing 25 mM imidazole for a total of 2–3 column volumes, 
being sure to collect equal volume sample fractions throughout the process. The washing step is 
critical to remove weakly bound protein contaminants enhancing the captured OMV purity. 
Captured vesicles were then eluted with 1–2 column volumes of 250 mM imidazole. Dialysis or 
membrane filtration was then used to buffer exchange the purified OMV fractions to remove the 
imidazole. Specifics for each method and manufacturer vary slightly, and following the supplied 
manufacturer's information for the slurry and packed resin processing protocols is recommended. 
The chromatogram of the capture, flow-through of non-mutant OMVs/contaminants and 
selective release of the mutant Lpp′-OmpA-His6 OMVs by the addition of imidazole demonstrate 
a successful affinity separation (Fig. 2A). Vesicles were analyzed by NanoSight before and after 
affinity purification to verify that binding and elution from the solid resin surface did not 
negatively impact vesicle size distribution or morphology (Fig. 2B). The vesicles displayed a 
nearly identical size distribution pre- and post-IMAC purification. Despite the small 280 nm 
elution peak present in the native vesicle sample that did not display the Lpp′-OmpA-His6, no 
vesicles were captured by the Ni-NTA resin, as determined by NanoSight. It is common for there 
to be some off-target binding of histidine-rich proteins to the Ni-NTA column. In the presence of 
a high concentration of target protein/OMVs, these weakly bound off-target proteins can be largely 
outcompeted or removed by increasing the imidazole concentration in the wash step. Analysis of 
the Lpp′-OmpA-His6 OMV confirmed that the vesicles retained their native morphology, and 
demonstrated that a diverse OMV size distribution could be captured and eluted utilizing IMAC 
(Fig. 2C). Nanosight and SEM analysis of native OMVs was performed in parallel to provide for 
qualitative comparison of wild-type and mutant OMV (data not shown). No significant differences 
were observed with either method of analysis. 
 Fig. 2 A) Chromatogram for a representative purification of His-tag vesicles purified directly 
from E. coli culture media via IMAC Ni-NTA resin showing the capture (Fractions 1-10), flow-
through of non-mutant OMV and contaminants (Fractions 11-44) and selective release of the 
Lpp′-OmpA-His6 OMV by addition of imidazole (Fractions 45-55). B) NanoSight histograms of 
pre- and post-IMAC purified vesicles demonstrating no apparent impact to vesicle size post 
binding and elution from the Ni-NTA resin. No native OMVs were observed in the elution 
fraction from native OMV Ni-NTA purification. C) SEM image of purified Lpp′-OmpA-His6 
OMV. 
 
3.4 Column performance 
When comparing the His-tag vesicle chromatogram with that of native vesicles, we noticed 
a high level of absorbance in fractions 10-25 that was not present in the native vesicle sample. This 
was a potential indication that weakly bound His-tag vesicles were being lost during the 
purification process. NanoSight analysis is limited to only determining particle size and quantity 
but is incapable of differentiating OmpA-His6 vesicles from native vesicles. For this reason, a 
western blot analysis was carried out, utilizing the included His-tag, to track whether or not all of 
the mutant vesicles were captured. As suggested by the His-tagged vesicle chromatogram, a 
significant fraction of the His-tagged vesicles were lost in the flow-through and wash fractions 
(Fig. 3). This was an unexpected result, as the purification was carried out well below the 
documented resin binding capacity of the commercially available Ni-NTA resin of ≤60 mg of a 
28 kDa protein per mL of settled resin. 
 Fig. 3 Western blot of the elution profile of Lpp′-OmpA-His6 mutant vesicles from Ni-NTA 
resin utilizing an anti-His-tag antibody. This separation demonstrates oversaturation of the 
column in which much of the mutant vesicles are lost in the initial flow-through. Captured 
vesicles were washed and subsequently eluted with the addition of imidazole. Despite exceeding 
the column capacity, the separation of flow-through and elution by a wash region containing 
very few mutant OMV demonstrates successful capture and elution of target OMV. 
 
To investigate the apparent limited loading capacity of the Ni-NTA resin, OMVs were 
incubated with a lipophilic dye (DiI) and then incubated with Ni-NTA resin under OMV saturating 
conditions. The resin was washed to ensure that all bound OMVs were due to specific binding of 
the His-tag to the immobilized metal ion. The resin was then visualized on a confocal microscope 
and, through a combination of center slice and total intensity projections, we observed complete 
surface coverage of the Ni-NTA resin by the mutant vesicles, with no infiltration of the particles 
beyond the resin surface (Fig. 4A). There was no observed non-specific staining, transfer of 
lipophilic dye to the resin beads or autofluorescence observed in unlabeled OMV or dye-exposed 
resin samples (Supporting Information Fig. S3). Scanning electron microscopy (SEM) was also 
performed on the vesicle-bound resin samples to directly visualize the vesicles on the surface 
(Fig. 4B). 
 Fig. 4 A) Confocal images of the transmission (left) and center slice fluorescence (right) of DiI 
dye labeled His-tagged OMV showing capture by the Ni-NTA resin. These saturated resin beads 
are representative of purification carried out in Fig. 3 in which a large portion of mutant OMVs 
were lost in flow-through. This demonstrates how OMVs are too large to permeate into the resin 
which reduces the overall resin binding capacity. B) SEM image of the OMV-saturated Ni-NTA 
resin surface showing complete blocking of the resin pores. 
 
Nearly all commercially available IMAC resins utilized for protein purification are 
optimized for capturing proteins that are <300 kDa. Most proteins fall within that range; however, 
vesicles are considerably larger. The resin selected for this representative purification had a 
documented molecular weight exclusion limit of 4000 kDa, which is typical for a 6% cross-linked 
agarose resin bead. To determine a theoretical molecular weight estimate for a 100 nm diameter 
OMV if it was a solid protein of the same size, we extrapolated using the size and weight of BSA 
(bovine serum albumin), which is a 66.5 kDa, 14 × 4 × 4 nm protein. Using this ratio, the apparent 
MW of a 100 nm diameter OMV would be equivalent to 155,000 kDa, making it nearly 40-fold 
larger than the MW exclusion limit of the 6% cross-linked agarose resin. With this in mind, it is 
not surprising that resin binding capacity is greatly reduced considering the OMV are too large to 
enter the resin pores to access internal Ni2+ ions to coordinate. While overall resin binding capacity 
is greatly reduced at 2 ± 0.5 mg/mL of resin, more resin can be utilized to effectively capture more 
OMV, taking advantage of how scalable this technique is. Binding capacity of the resin may also 
be increased through designing an IMAC resin bead with a larger molecular weight exclusion limit 
specific for this application. Alternatively, materials such as Ni-NTA functionalized magnetic 
beads could also be employed for purification, as these materials are available in a range of sizes 
which could convey improved capture efficiency when combined with a batch capture/wash 
protocol. 
3.5 Advanced purification capabilities 
Due to the diverse roles that OMVs play in bacterial and mammalian cellular communities, 
there may be very discrete subpopulations within the bulk OMV population specific to performing 
each unique task [30]. Current OMV purification techniques largely lack the ability of 
differentiating subpopulations of interest from the bulk OMV populations, which is of great 
interest when elucidating complex cell-cell communication and disease progression pathways. 
Despite having reduced resin binding capacity, this technique can be implemented for purifying a 
well-defined OMV subpopulation from a complex mixture of non-mutant bulk OMV and free 
culture proteins (Fig. 5A). To demonstrate this, mutant OmpA-His6 OMVs were spiked into a 
culture of native OMVs and purified utilizing IMAC purification as described above. To ensure 
that all His-tagged OMV were captured by the resin, an excess of Ni-NTA resin was used. The 
OMV-bound resin was visualized by SEM to show individual OMVs bound to the resin surface 
(Fig. 5B). The resulting affinity separation was also analyzed by western blot, demonstrating a 
high capture efficiency with nearly no target OMV being lost in the flow-through fractions 
(Fig. 5C). By linking the external affinity epitope utilized for purification with internal 
modification sites for packaging cargo, this purification technique can also be utilized to separate 
cargo-loaded OMVs from non-loaded OMVs, which no other technique is currently capable of 
doing. This advanced purification capability has numerous applications in the production and 
purification of various pharmaceutical and industrial biological compounds. 
 Fig. 5 A) Schematic representation of selective affinity purification of His-tag protein-loaded 
OMVs from native non-loaded OMV and other culture media contaminants. B) SEM image of 
high Ni-NTA resin to OmpA-His3 vesicle ratio. This technique allows direct visualization of the 
OmpA-His3 vesicles bound to the surface of the Ni-NTA resin. C) Western blot of the elution 
profile of OmpA-His3 mutant vesicles from Ni-NTA resin utilizing an anti-His-tag antibody. 
This separation demonstrates a high capture efficiency and recovery of a minutely expressed 
mutant His-tagged vesicle from a complex mixture such as conditioned bacterial culture media. 
 
In conclusion, described here is a method for the IMAC purification of bacterial outer 
membrane vesicles by incorporating a non-native His-tag into a permissive externally facing 
protein domain for capture on a Ni-NTA resin. This technique allows for selection of OMV 
subpopulations at the purification level, since only vesicles containing the His-tag will adhere to 
the resin and be purified. The technique can be further advanced through incorporation of a 
cleavable linker that will allow purified OMVs to be restored to their native composition for use 
in further experimental procedures in which the presence of a His-tag may impact results [31]. For 
incorporating this purification technique into a pharmaceutical downstream OMV processing 
scheme, it may be beneficial to incorporate the His-tag via homologous recombination to ensure 
that all secreted OMVs possess the affinity tag. While bacterial OMVs were utilized for the proof 
of concept purification described here, this technique can be adapted for use in developing 
analogous purification strategies for mammalian exosomes, extracellular vesicles and liposomes 
across a wide array of diagnostic, therapeutic, industrial and environmental remediation 
applications. 
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Supporting Information Figures: 
Figure S1:  Lpp’-OmpA-His-tag and OmpA-His-tag protein sequences 
Figure S2:  SDS-PAGE and Western Blot for OmpA-His-tag expression 
Figure S3:  DiI Confocal Image controls for Ni-NTA resin and labeled OMV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lpp’-OmpA-His-tag: Leader sequence in yellow, lipoylation sequence (Lpp’) in red, OmpA (46-
159) in grey, and 6xHis-tag in blue. 
MKATKLVLGAVILGSTLLAGCSSNAKIDQNNGPTHENQLGAGAFGGYQVNPYVGFEM
GYDWLGRMPYKGSVENGAYHAQGVQTAKLGYPITDDLDIYTRLGGMVWRADTKSN
VYGKNHDTGVSPVFAGGVEYAITPEIATRGGGSGGGSGGGSSTAAALEHHHHHH* 
 
OmpA-His-tag: Leader sequence in yellow, OmpA in grey, external facing 3xHis-tag in blue, 
and internal facing terminal 6xHis-tag for Western Blotting purposes in purple. 
MKKTAIAIAVALAGFATVAQAGGGSPRAPKDNTWYTGAKLGWSQYHDTGFINNNGPT
HENQLGAGAFGGYQVNPYVGFEMGYDWLGRMPYKGSHHHVENGAYKAQGVQLTAK
LGYPITASDDLDIYTRLGGMVWRADTKSNVYGKNHDTGVSPVFAGGVEYAITPEIATRL
EYQWTNNIGDAHTIGTRPDNGMLSLGVSYRFGAAALEHHHHHH* 
Figure S1.  His-tag protein Sequences.   
 
 
 
 
 
 
 
 
 
Figure S2.   (Left)  Coomassie stained SDS-PAGE of the culture cell pellets from an initial, pre-
induction sample, to post overnight expression of mutant OmpA-His-tag. Ultracentrifuge 
concentrated culture supernatant was used to isolate the total OMV population to demonstrate 
the presence of the mutant OmpA-His-tag compared to a non-mutant control OMV sample 
lacking the OmpA-His-tag (final lane of the SDS-PAGE).   (Right)  Western blot of OmpA-His-
tag over a range of IPTG induction concentrations, utilizing an anti-His-tag primary antibody to 
probe for the mutant OmpA-His-tag form of the protein.   
 
Figure S3.  Confocal images of transmission (Top Row) and center slice fluorescence (Bottom 
Row) were taken to assess OMV capture by the Ni-NTA resin and determine whether or not the 
OMVs would be capable of permeating the resin.  Pictured are the following: IMAC resin alone 
(Left), IMAC resin incubated with DiI dye (Center), and IMAC resin with DiI dye stained 
OmpA-His-tag vesicles (Right). Ni-NTA resin particles range in size from 40-100 µm in 
diameter.  All transmission and fluorescence images were taken on a Nikon Eclipse TE2000-E 
confocal microscope using EZ-C1 spectral imaging software.  All fluorescence images were 
taken with a 20x objective using a 650LP red filter, medium (60 m) pinhole and 98 gain. Image 
analysis and z-stacking was performed on NIS Elements AR imaging software 3.10.  All images 
were processed with identical parameters. 
 
